Actualités

Mont-Saint Guibert, Belgium, 29 July, 2020: Novadip Biosciences ("Novadip" or "the Company"), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform

CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development

• The UCLouvain created, through its technology transfer office Sopartec, a new European university fund of €32m, VIVES Inter-University Fund
• Its ambition? Accelerate the transformation of research

1st July 2020 – Award-winning start-up e-peas continues to underline its reputation as the go-to supplier of advanced energy harvesting solutions, having just completed its latest funding round.  

Wi

Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome

Mont-Saint Guibert, Belgium, 4 June, 2020: Novadip Biosciences (

Animal health company focused on combatting viral infections in livestock

LEUVEN, Belgium, May 28th, 2020 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of

• Axinesis, the Walloon company specialized in medical devices for neurological rehabilitation, announces the CE mark for its new product, the REAtouch®.
• It is a medical device for patients

– Initial data from the dose escalation portion of the Phase 1/2a trial in 21 cancer patients with advanced solid tumors shows EOS-850 was well tolerated with no dose-limiting toxicities observed –

–

Walloon biotech iTeos Therapeutics completes a new round of $125 million with historical investors and 5 new leading U.S. funds active in initial public offering (IPO). This is one of the largest

As of February 21st, Prof. Etienne Sokal, M.D., Ph.D., has stepped back from his operational role as Group CMO and will transition to the position of Chairman of Promethera®’s Scientific & Medical

Belgian biotechnology company ViroVet announced today that it has made its expertise, research staff as well as part of its research facility available to support COVID19 research and sample testing

Initial clinical data expected in 1H 2021

Cambridge, MA and Gosselies, Belgium – February 27, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing